As demand for Ready-to-Use (RTU) elastomer components used in injectable drug product packaging continues to grow, pharmaceutical manufacturers must balance sterility assurance, regulatory expectations, product quality and operational efficiency. In the context of current EMA guidance, selecting an appropriate sterilization method requires careful consideration of validation requirements, contamination control strategies, and packaging integrity.
In this webinar, Antoine Menard from Aptar Pharma and Alain Euzen from Axys-Network will compare gamma irradiation and moist heat sterilization for Ready-to-Use elastomer closure components used in the packaging of injectable drug products. Drawing on a risk assessment conducted in line with current regulatory expectations, they will explore the key factors influencing sterilization method selection, including sterility assurance, residual humidity, particle generation, packaging integrity, and validation requirements.
Attendees will gain practical insight into the benefits, limitations, and risk considerations associated with each approach, while learning how ISO 11137 supports the validation of gamma-irradiated RTU components.
Join Aptar Pharma and Axys-Network to discover key considerations for selecting and validating sterilization methods for RTU elastomer components and strengthen confidence in your sterility assurance strategy.
Key Learning Objectives
- Understand how a risk-based approach can support sterilization method selection for RTU elastomer components
- Compare the advantages and limitations of moist heat and gamma irradiation sterilization
- Learn the key validation requirements for gamma irradiation under ISO 11137
- Evaluate how sterilization choices can impact sterility assurance, packaging integrity and manufacturing operations